Codexis, Inc. (CDXS): Price and Financial Metrics

Codexis, Inc. (CDXS)

Today's Latest Price: $12.42 USD

0.19 (-1.51%)

Updated May 29 6:55pm

Add CDXS to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 336 in Biotech

See all "A" rated Strong Buy stocks

CDXS Stock Summary

  • CDXS's price/sales ratio is 10.85; that's higher than the P/S ratio of 89.37% of US stocks.
  • CDXS's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 21.73% of US stocks.
  • Over the past twelve months, CDXS has reported earnings growth of 27.12%, putting it ahead of 75.78% of US stocks in our set.
  • Stocks that are quantitatively similar to CDXS, based on their financial statements, market capitalization, and price volatility, are CERS, HTBX, CAPR, PTCT, and PSNL.
  • Visit CDXS's SEC page to see the company's official filings. To visit the company's web site, go to
CDXS Daily Price Range
CDXS 52-Week Price Range

CDXS Stock Price Chart More Charts

CDXS Price/Volume Stats

Current price $12.42 52-week high $19.32
Prev. close $12.61 52-week low $8.43
Day low $12.12 Volume 386,900
Day high $12.65 Avg. volume 416,188
50-day MA $11.06 Dividend yield N/A
200-day MA $13.65 Market Cap 733.00M

Codexis, Inc. (CDXS) Company Bio

Codexis, Inc. develops biocatalysts for the pharmaceutical and fine chemicals markets in the United States and internationally. The company offers Codex biocatalyst panels and kits to pharmaceutical companies that are engaged in drug development and the marketing of approved drugs to allow them to screen and identify possible enzymatic manufacturing processes for their drug candidates and their marketed products. The company was founded in 2002 and is based in Redwood City, California.

CDXS Latest News Stream

Event/TimeNews Detail
Loading, please wait...

CDXS Latest Social Stream

Loading social stream, please wait...

View Full CDXS Social Stream

Latest CDXS News From Around the Web

Below are the latest news stories about Codexis Inc that investors may wish to consider to help them evaluate CDXS as an investment opportunity.

Codexis to Participate in Two Virtual Investment Conferences

REDWOOD CITY, Calif., May 27, 2020 -- Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces that management will participate in two virtual investment.

Yahoo | May 27, 2020

Should Codexis Investors Prepare for Slower Growth?

The company's largest source of revenue will be affected by the pandemic, but there appears to be a silver lining.

Yahoo | May 22, 2020

Codexis to Present at the UBS Virtual Healthcare Conference

REDWOOD CITY, Calif., May 11, 2020 -- Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces that management will present at the UBS Virtual Healthcare.

Yahoo | May 11, 2020

H.C. Wainwright Sticks to Their Buy Rating for Codexis

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Codexis (NASDAQ:CDXS) on Monday, setting a price target of $21, which is approximately 71.71% above the present share price of $12.23.

Yahoo | May 11, 2020

Codexis(CDXS) Q1 2020 Earnings Call Transcript

Ladies and gentlemen, thank you for standing by, and welcome to the first-quarter 2020 Codexis earnings conference call. This is Bruce Voss with LHA. Thank you all for participating in today's Codexis call to discuss first-quarter 2020 financial results and recent business progress.

Yahoo | May 9, 2020

Read More 'CDXS' Stories Here

CDXS Price Returns

1-mo 12.70%
3-mo 8.95%
6-mo -18.98%
1-year -31.38%
3-year 179.10%
5-year 217.65%
YTD -22.33%
2019 -4.25%
2018 100.00%
2017 81.52%
2016 8.75%
2015 67.86%

Continue Researching CDXS

Here are a few links from around the web to help you further your research on Codexis Inc's stock as an investment opportunity:

Codexis Inc (CDXS) Stock Price | Nasdaq
Codexis Inc (CDXS) Stock Quote, History and News - Yahoo Finance
Codexis Inc (CDXS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 1.0504 seconds.